FindTrial
Sign In

Feasibility study on the amplification of EGFR gene from rare cells in human peripheral blood for auxiliary diagnosis of benign and malignant pulmonary nodules

Feasibility study on the amplification of EGFR gene from rare cells in human peripheral blood for auxiliary diagnosis of benign and malignant pulmonary nodules

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500102747
Enrollment
Unknown
Registered
2025-05-19
Start date
2024-07-15
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary nodules

Interventions

Gold Standard:Low dose spiral CT
Index test:EGFR amplification of rare cells in human peripheral blood

Sponsors

Sichuan Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Subjects in whom CT or LDCT detected single or multiple lung nodules of 6-30mm, the risk of nodules could not be determined, and further pathological diagnosis was clinically recommended; 2. >=18 years old; 2.Sign informed consent and agree to follow the sampling, evaluation, and interview requirements for this study.

Exclusion criteria

Exclusion criteria: 1.A woman who is breastfeeding, pregnant or trying to become pregnant; 2.Severe heart, lung, liver or kidney dysfunction or mental disorder; 3.Sampling problems that do not meet the requirements of histopathological examination; 4.History of malignant tumor within 5 years.

Design outcomes

Primary

MeasureTime frame
Accuracy of peripheral blood measurement;—

Countries

China

Contacts

Public ContactXuefeng Leng

Sichuan Cancer Hospital

leng724@163.com+86 28 85420681

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026